ALDH1A1 and neoplasm: Most of the subjects in this study were under the categories of younger than 50 years (53.70%), T4 tumor size (44.44%), involvement of the N1 lymph node (57.41%), no metastasis (72.22%), grade 2 histological grading (51.84%), Ki67 ≥ 20% (83.33%), stages 2 and 3 (35.19%), chemotherapy TC (48.15%), no recurrence (77.78%), radiotherapy (57.41%), and negatively expressed ALDH1 (61.11%) (Table 1).